CN100544759C - Grippal medicinal tea of a kind of control and compound method thereof - Google Patents
Grippal medicinal tea of a kind of control and compound method thereof Download PDFInfo
- Publication number
- CN100544759C CN100544759C CNB2007100518896A CN200710051889A CN100544759C CN 100544759 C CN100544759 C CN 100544759C CN B2007100518896 A CNB2007100518896 A CN B2007100518896A CN 200710051889 A CN200710051889 A CN 200710051889A CN 100544759 C CN100544759 C CN 100544759C
- Authority
- CN
- China
- Prior art keywords
- fructus
- grippal
- radix astragali
- medicinal tea
- tritici levis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015091 medicinal tea Nutrition 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title claims abstract description 5
- 241000628997 Flos Species 0.000 claims abstract description 24
- 239000009636 Huang Qi Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- 241000245240 Lonicera Species 0.000 claims abstract description 11
- 239000000047 product Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000796 flavoring agent Substances 0.000 claims abstract description 7
- 235000019634 flavors Nutrition 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 241001570521 Lonicera periclymenum Species 0.000 claims abstract description 5
- 241001122767 Theaceae Species 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 238000005516 engineering process Methods 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 5
- 235000013616 tea Nutrition 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 3
- -1 mixing Substances 0.000 claims abstract 3
- 206010011224 Cough Diseases 0.000 abstract description 2
- 230000002605 anti-dotal effect Effects 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 239000012567 medical material Substances 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 22
- 206010022000 influenza Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Grippal medicinal tea of a kind of control and compound method thereof is characterized in that the weight portion of each raw material is: the Radix Astragali 100～2000, Flos Lonicerae 100～2000, Fructus Jujubae 100～2000, Fructus Tritici Levis 100～2000; Preparation technology: above four flavors, half of extracting honeysuckle quantity is ground into fine powder, and be standby; All the other Flos Loniceraes and the Radix Astragali, Fructus Tritici Levis, Fructus Jujubae decoct with water 2 times, and each 2 hours, merge decoction liquor, filter, it is 1.20～1.25 clear paste that filtrate is concentrated into relative density, adds the Flos Lonicerae fine powder, mixing, granulate, dry, splitting is made bag tea agent, promptly gets product.The present invention prevents and treats grippal medicinal tea, and raw material is the medicine-food two-purpose medical material, and is with low cost, and product has strengthening vital QI to eliminate pathogenic factors, and QI invigorating antidotal effect is applicable to treatment body wind syndrome caused by deficiency heat symptom-complex flu, cough.
Description
Technical field
The invention belongs to grippal medicinal tea of control and compound method thereof.
Background technology
Influenza (influenza), be called for short influenza, be the acute respiratory infectious disease that is caused by influenza virus, be the common clinical frequently-occurring disease, all there is large-scale outburst and popular annual Winter-Spring, have incubation period short, infectiousness is strong, the sickness rate height, characteristics such as popular wide and mortality rate height are the still out of contior so far pandemic infection diseases of the mankind, its hazardness mainly is severe complications, often jeopardizes infant, old people and immunologic hypofunction person's life.Influenza virus is divided first (A), second (B), third (C), three classes, and wherein, influenza A virus often occurs with popular form, can cause worldwide being very popular.Existing five worldwide pandemic records since this century, wherein once popular in 1918 only with regard to dead more than 2,000 ten thousand people.Owing to once brought heavy disaster to the mankind, influenza becomes first infectious disease of carrying out global monitoring, but the mankind still can't control fully to its harm so far.
Through research for many years, prevent and treat the existing amantadine (Amantadine) of modern medicines, the rimantadine (Rimatadine) of influenza, neuraminidase inhibitor mainly comprises zanamivir (Zanamivir) and Oseltamivir (Oseltamivir), these medicines are affirmed the therapeutic effect of influenza, taking convenience, but easily produce drug resistance, also can cause simultaneously untoward reaction such as dizzy, insomnia, regurgitation.At present the effective measures of flu-prevention are inoculation influenza vaccines; but because antigenic variation often takes place in influenza virus surface glycoprotein (mainly being hemagglutinin HA and neuraminidase NA); make it might escape host's immunoprotection; add some problems that in vaccine uses, exist; make the vaccine coverage rate little, the preventive effect of vaccine has only 70%～90%.Influenza virus attenuated vaccine and recombinant vaccine etc. are also in development.
Because chemicals is used for the treatment of the viral disease part that still has some deficits, thereby people have turned to sight on the natural drug.Chinese medicine is the precious deposits of China and even world medicine as natural drug, the treatment of relevant viral disease is early on the books in motherland's medical science, and accumulated rich experience, especially to the treatment of influenza, not only have suppress virus replication, stop pathological changes caused by virus, regulate immunologic function, improve pulmonary circulation, comprehensive effect such as antalgic and inflammation relieving, and toxic and side effects is little or nothing, low price, and the medicine source is extensive.Therefore, Chinese medicine has special advantages and vast potential for future development aspect the influenza preventing and treating.
Summary of the invention
The technical problem to be solved in the present invention provides the grippal Chinese herbal medicine medicinal tea of a kind of new control, for influenza patient medication provides new selection.
The present invention solves the problems of the technologies described above with following technical scheme:
The weight portion of each active ingredient raw materials medicine is:
The Radix Astragali 100～2000 Flos Loniceraes 100～2000 Fructus Jujubaes 100～2000 Fructus Tritici Levis 100～2000
Preparation method is:
More than four flavors, the Flos Lonicerae powder of half quantity is broken into fine powder, standby; All the other Flos Loniceraes and the Radix Astragali, Fructus Tritici Levis, Fructus Jujubae decoct with water 2 times, merge decoction liquor, filter, and filtrate is concentrated into the clear paste that relative density is 1.20～1.25 (70 ℃), add the Flos Lonicerae fine powder, and mixing is granulated, oven dry, and bag tea agent is made in packing, promptly.
The present invention prevents and treats grippal medicinal tea, and raw materials used is the medicinal herbs most in use of medicine-food two-purpose, and the medicine source is extensive, and is with low cost, and the product that makes has strengthening vital QI to eliminate pathogenic factors, and QI invigorating antidotal effect is applicable to treatment body wind syndrome caused by deficiency heat symptom-complex flu, cough.Pharmacological evaluation confirms that this product has effects such as significant resisiting influenza virus and raising immunity.Toxicity test proves that this product toxicity is very little, takes safety.The preparation technology of product is simpler, system easy to control the quality.
Description of drawings
Fig. 1 is the flow chart of the grippal medicinal tea of preparation control of the present invention.
The specific embodiment
Through proved recipe is studied for a long period of time, screens, relatively and after updating, the applicant selected for use by the Radix Astragali, Flos Lonicerae, Fructus Jujubae, Fructus Tritici Levis totally four flavor Chinese herbal medicine as the raw material of this Chinese medicine medicinal tea.
Above-mentioned the existing of medical material of respectively distinguishing the flavor of is described below:
The Radix Astragali: sweet tepor, to return spleen, lung meridian, tonifying Qi and lifting yang is arranged, benefit is defended functions such as consolidating superficial resistance, the gas of energy spleen reinforcing lung, " being the QI invigorating key medicine ".
Flos Lonicerae: sweet cold, return the lung large intestine channel, heat-clearing and toxic substances removing is arranged, light a surname evacuates function.
Fructus Jujubae: Fructus Jujubae, Gan Wen returns spleen, stomach warp.Invigorating the spleen and replenishing QI is arranged, and nourishing blood to tranquillize the mind relaxes property of medicine effect.
Fructus Tritici Levis: sweet, cool, the GUIXIN warp has QI invigorating relieving restlessness effect.
The weight portion of each active ingredient raw materials medicine is:
The Radix Astragali 100～2000 Flos Loniceraes 100～2000 Fructus Jujubaes 100～2000 Fructus Tritici Levis 100～2000
Preparation method is:
More than four the flavor, half Flos Lonicerae powder is broken into fine powder, standby.All the other Flos Loniceraes and the Radix Astragali, Fructus Tritici Levis, Fructus Jujubae decoct with water 2 times, and each 2 hours, merge decoction liquor, filter, filtrate is concentrated into the clear paste that relative density is 1.20～1.25 (70 ℃), adds the Flos Lonicerae fine powder, and mixing is granulated, oven dry, bag tea agent is made in packing, promptly gets product.
The pharmacodynamic study result of medicinal tea of the present invention is as follows:
1. medicinal tea of the present invention is to SARS suspected patient Immune Effects
Take medicinal tea treatment front and back SARS suspected patient whole blood of the present invention and serum, measure t lymphocyte subset group, immunity of organism globulin content, complement component, interleukin II, 10, interferon-, IFN-α, tumor necrosis factor.The result shows that medicinal tea of the present invention can significantly reduce SARS suspected patient T cell subsets decline scope, promotes the rise of convalescent period T cell subsets.Take medicine preceding and take medicine back 10,20d immunity of organism globulin, the equal not statistically significant of complement component content difference.Serum IL-2, IFN-γ all raise after 13 patients took medicine, and with the preceding comparing difference of taking medicine statistical significance were arranged.Serum il-10 comparing difference not statistically significant before and after taking medicine.
2. the external resisiting influenza virus effect research of medicinal tea of the present invention
Set up external viral infection model; by dosing behind the first infective virus, first dosing postoperative infection virus, three kinds of administering modes of infective virus dosing simultaneously, adopt cytopathy political reform and mtt assay to observe medicinal tea of the present invention and of the protective effect of each single medicinal material to the influenza virus infection cell.The result shows that no matter to A1, A3 influenza virus, medicinal tea of the present invention cell survival amount under three kinds of application methods all is significantly increased than the virus control group, and suppression ratio is higher than each single medicinal material and ribavirin matched group.
3. medicinal tea of the present invention is to effect of immunologic function
The employing sheep red blood cell (SRBC) causes the generation of mice hemolytic antibody, the mice carbon granule is cleaned up and the experiment of 2,4 dinitrochlorobenzene induced mice delayed hypersensitivitys, observes medicinal tea of the present invention to effect of immunologic function.The result shows that medicinal tea of the present invention can promote hemolysin to generate, improves the reticuloendothelial system phagocytic function and promote the mice delayed hypersensitivity that 2,4 dinitrochlorobenzene bring out.
4. medicinal tea of the present invention is to the poverty-stricken syndromic protective effect research of rats breathing
Tail vein injection oleic acid duplicates rat ARDS model, treated with medicinal tea of the present invention, and after the administration the 4th day, arterial blood gas, lung homogenate superoxide dismutase activity, mda content and the content of nitric oxide of observing rat; Detect the lung tissue tumor necrosis factor with the SABC method and express, and do the pathology histological examination.The result shows that medicinal tea of the present invention can improve the PO of ARDS rat
2, reduce PCO
2, the SOD vigor is obviously strengthened, MDA and NO content reduce, and TNF-α positive expression reduces, and lung tissue pathology changes and obviously alleviates.
Embodiment 1:
Prescription Radix Astragali 100g Flos Lonicerae 2000g Fructus Jujubae 1000g Fructus Tritici Levis 100g
Above four flavors of method for making, half 1000g of extracting honeysuckle total amount is ground into fine powder, and is standby.All the other Flos Loniceraes and the Radix Astragali, Fructus Jujubae, Fructus Tritici Levis decoct with water 2 times, and each 2 hours, merge decoction liquor, filter, filtrate is concentrated into the clear paste that relative density is 1.20～1.25 (70 ℃), adds the Flos Lonicerae fine powder, and mixing is granulated, oven dry, oven dry, bag tea agent is made in packing, promptly.
Embodiment 2:
Prescription Radix Astragali 1000g Flos Lonicerae 1000g Fructus Jujubae 2000g Fructus Tritici Levis 1000g
Method for making half 500g of extracting honeysuckle total amount as different from Example 1 is ground into fine powder, and all the other Flos Loniceraes and other medicines decoct, filter, concentrate, and be surplus with embodiment 1.
Embodiment 3:
Prescription Radix Astragali 2000g Flos Lonicerae 100g Fructus Jujubae 100g Fructus Tritici Levis 2000g
Method for making half 50g of extracting honeysuckle total amount as different from Example 1 is ground into fine powder, and all the other Flos Loniceraes and other medicines decoct, filter, concentrate, and be surplus with embodiment 1.
Claims (2)
1. prevent and treat grippal medicinal tea for one kind, it is characterized in that the weight portion of each raw material is:
The Radix Astragali 100～2000 Flos Loniceraes 100～2000 Fructus Jujubaes 100～2000 Fructus Tritici Levis 100～2000.
One kind the control grippal medicinal tea compound method, it is characterized in that:
The weight portion of each raw material is:
The Radix Astragali 100～2000 Flos Loniceraes 100～2000 Fructus Jujubaes 100～2000 Fructus Tritici Levis 100～2000;
Preparation technology:
More than four the flavor, half of extracting honeysuckle quantity is ground into fine powder, and be standby; All the other Flos Loniceraes and the Radix Astragali, Fructus Tritici Levis, Fructus Jujubae decoct with water 2 times, and each 2 hours, merge decoction liquor, filter, it is 1.20～1.25 clear paste that filtrate is concentrated into relative density, adds the Flos Lonicerae fine powder, mixing, granulate, dry, splitting is made bag tea agent, promptly gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100518896A CN100544759C (en) | 2007-04-12 | 2007-04-12 | Grippal medicinal tea of a kind of control and compound method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100518896A CN100544759C (en) | 2007-04-12 | 2007-04-12 | Grippal medicinal tea of a kind of control and compound method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101028456A CN101028456A (en) | 2007-09-05 |
| CN100544759C true CN100544759C (en) | 2009-09-30 |
Family
ID=38714114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100518896A Active CN100544759C (en) | 2007-04-12 | 2007-04-12 | Grippal medicinal tea of a kind of control and compound method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100544759C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101263856B (en) * | 2008-04-15 | 2011-09-14 | 吴小建 | Agrimony health-care tea |
-
2007
- 2007-04-12 CN CNB2007100518896A patent/CN100544759C/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 黄芪、金银花提取物体外抗禽流感病毒的试验研究. 王国霞，邹海棠，梅春升等.中兽医学杂志，第3期. 2005 |
| 黄芪、金银花提取物体外抗禽流感病毒的试验研究. 王国霞，邹海棠，梅春升等.中兽医学杂志，第3期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101028456A (en) | 2007-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100457176C (en) | Chinese medicinal preparation for curriculum of physical and fatigue reducing | |
| CN103520577A (en) | Medicine-and-food dual-purpose preparation for treating pneumoconiosis, clearing away lung-heat and nourishing heart and preparation method for medicine-and-food dual-purpose preparation | |
| CN103800672A (en) | Health care capsule for relieving physical fatigue and preparation method of health care capsule | |
| CN105456897A (en) | Traditional Chinese medicine composition containing argy wormwood leaf for treating spleen deficiency gasterasthenia type chronic gastritis | |
| CN106579419A (en) | Fatigue alleviating, physical strength restoring and energy replenishing functional food composition | |
| CN100493578C (en) | Chinese medicine composition for treating thin body and delicate constitution, and preparing method | |
| CN100544759C (en) | Grippal medicinal tea of a kind of control and compound method thereof | |
| CN101785811A (en) | Traditional Chinese medicine for senile pruritus treatment | |
| CN100431594C (en) | Compound preparation for treating summer wet type cold and its preparing method | |
| CN102178798A (en) | Preparation for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
| CN101745048B (en) | Medicine for treating type II diabetes and resisting aging | |
| CN104225425A (en) | Chinese herbal preparation for enhancing immunity, improving sleep and preventing cardio-cerebrovascular disease, and preparation method thereof | |
| CN101249181B (en) | Removing blood stasis Tongmai Chinese medicine compound preparations and method of preparing the same | |
| CN104491810B (en) | A kind of Chinese medicine for treating AIDS deficiency of qi and blood and damp and hot ailment said due to cold or exposure card | |
| CN102846882A (en) | Chinese medicinal composition for reducing blood sugar | |
| CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
| CN111686200A (en) | Traditional Chinese medicine composition and decoction for treating diabetes as well as preparation method and application of traditional Chinese medicine composition and decoction | |
| CN104840737A (en) | Traditional Chinese medicine composition with qi invigorating and lung moistening functions and preparation method and application thereof | |
| CN101518575B (en) | Traditional Chinese medicine for treating diabetic insomnia | |
| CN104758578A (en) | Traditional Chinese medicine composition for treating palpitation | |
| CN103721229A (en) | Traditional Chinese medicinal composition for treating infantile cough and asthma and preparation method thereof | |
| CN110478406A (en) | It is a kind of to have effects that alleviate Chinese medicine composition of hypothyroidism and preparation method thereof, application and product | |
| CN1425441A (en) | Compound macrostem onion preparation for curing chronic obstructive lung disease and its preparing method | |
| CN108743757A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating insomnia | |
| CN103751283B (en) | A kind of Chinese medicine composition for the treatment of cardiopalmus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190509 Address after: 535008 Real Madrid Industrial Park, Qinzhou, the Guangxi Zhuang Autonomous Region Patentee after: Guangxi Baiqi Pharmaceutical Co., Ltd. Address before: No. 22 Shuangyong Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021 Co-patentee before: Lai Maoxiang Patentee before: Liu Huagang Co-patentee before: Leng Jing Co-patentee before: Zhu Dan Co-patentee before: Qin Xue |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for preventing influenza and its formulating method Effective date of registration: 20191106 Granted publication date: 20090930 Pledgee: Bank of China Limited Qinzhou Branch Pledgor: Guangxi Baiqi Pharmaceutical Co., Ltd. Registration number: Y2019450000020 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210825 Granted publication date: 20090930 Pledgee: Bank of China Limited Qinzhou Branch Pledgor: GUANGXI BAIQI PHARMACEUTICAL Co.,Ltd. Registration number: Y2019450000020 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tea agent for preventing and treating influenza and preparation method thereof Effective date of registration: 20210827 Granted publication date: 20090930 Pledgee: Bank of China Limited Qinzhou Branch Pledgor: GUANGXI BAIQI PHARMACEUTICAL Co.,Ltd. Registration number: Y2021450000035 |